Importantly, pharmacological inhibition of PI3K/AKT signaling disrupted ROR2-mediated cell adhesion, suggesting a therapeutic vulnerability that can be exploited in ROR2-high MM patients. The gene discussed is AKT1; the disease is Miyoshi myopathy.